Key Points
- Sukumar Nagendran sold 200,000 shares of Taysha on April 10 at an average price of $4.46 for $892,000, cutting his stake by 14.97% to 1,136,410 shares; the sale was executed under a pre‑arranged Rule 10b5‑1 trading plan.
- Taysha recently beat expectations with Q results of ($0.08) EPS vs. ($0.11) expected and revenue of $5.49M vs. $1.89M expected; the stock trades around $4.4 with a market cap of about $1.27B and carries a consensus Buy rating with a $11.64 price target.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) insider Sukumar Nagendran sold 200,000 shares of the firm's stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company's stock, valued at $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sukumar Nagendran also recently made the following trade(s):
- On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.61, for a total value of $124,091.98.
- On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $423,377.00.
Taysha Gene Therapies Stock Performance
TSHA opened at $4.42 on Tuesday. Taysha Gene Therapies, Inc. has a 12-month low of $1.13 and a 12-month high of $6.02. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -13.00 and a beta of 1.10. The business has a 50 day moving average of $4.53 and a 200-day moving average of $4.72. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. The business had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC increased its position in Taysha Gene Therapies by 3.6% during the 4th quarter. Intech Investment Management LLC now owns 71,069 shares of the company's stock worth $391,000 after buying an additional 2,443 shares during the period. Chicago Partners Investment Group LLC boosted its position in shares of Taysha Gene Therapies by 1.5% in the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company's stock valued at $916,000 after acquiring an additional 2,504 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Taysha Gene Therapies by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company's stock valued at $73,000 after acquiring an additional 2,765 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Taysha Gene Therapies by 7.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company's stock valued at $253,000 after acquiring an additional 3,008 shares in the last quarter. Finally, Xponance Inc. increased its position in Taysha Gene Therapies by 29.1% during the third quarter. Xponance Inc. now owns 16,575 shares of the company's stock worth $54,000 after acquiring an additional 3,738 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
TSHA has been the topic of several research reports. Chardan Capital reiterated a "buy" rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, January 5th. Wall Street Zen raised shares of Taysha Gene Therapies from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Finally, Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a "buy" rating in a report on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $11.64.
Get Our Latest Report on Taysha Gene Therapies
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
